Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 19, 2025PeerJOpen Access

Comparison of anti-PD-1/PD-L1-based regimens in relapsed/refractory diffuse large B-cell lymphoma: a meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

WJWenxin JiangTWTingyu WenPLPeng Liu

Discussion

Loading...

Member takes

Overview

Meta-analysis shows improved progression-free survival in DLBCL with combination therapy, indicating safer treatment options for relapsed cases.

Key Points

  • To assess the efficacy of PD-1/PD-L1 monoclonal antibody therapies in relapsed/refractory diffuse large B-cell lymphoma.
  • Conducted a meta-analysis of 29 studies
  • Searched multiple databases including PubMed and ClinicalTrials.gov
  • Registered on the PROSPERO platform
  • Combination therapy resulted in better progression-free survival (HR = 0.51)
  • Achieved higher overall response rate (30.5% vs. 10.3%)
  • No additional toxicities reported compared to monotherapy

Cite This Study

Jiang et al. (2025) studied this question.

synapsesocial.com/papers/6924fed1c0ce034ddc350e65https://doi.org/10.7717/peerj.20314
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis2025
  2. 2Efficacy and Safety of PD-1 Inhibitor-Based Regimens in Patients with Melanoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials2026
  3. 3Efficacy and safety of Programmed Death Ligand 1 inhibitors versus Programmed Death 1 inhibitors in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials2026
  4. 4Choosing the best first-line therapy for extensive-stage small-cell lung cancer: anti-PD-1 or anti-PD-L1 inhibitors?2025 · 3 citations
  5. 5Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis2025